VYNE Therapeutics
VYNE
48 hedge funds and large institutions have $116M invested in VYNE Therapeutics in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 14 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
0.11% less ownership
Funds ownership: 0.98% → 0.86% (-0.11%)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
2% less funds holding
Funds holding: 49 → 48 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
80% less capital invested
Capital invested by funds: $579M → $116M (-$463M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.37M |
| 2 |
Millennium Management
New York
|
+$2.31M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$810K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$637K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$539K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$16M |
| 2 |
VMI
VHCP Management II
New York
|
-$12.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$7.52M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Franklin Resources
San Mateo,
California
| – | -$7.52M | -2,778 | Closed |
|
|
NC
52
Nexthera Capital
New York
| – | -$2.79M | -1,030 | Closed |
|
|
GPP
53
Great Point Partners
Greenwich,
Connecticut
| – | -$1.95M | -722 | Closed |
|
|
MWNA
54
Marshall Wace North America
New York
| – | -$1.18M | -436 | Closed |
|
|
LCM
55
Landscape Capital Management
Englewood,
New Jersey
| – | -$1.12M | -414 | Closed |
|
|
EAM
56
Eventide Asset Management
Boston,
Massachusetts
| – | -$940K | -347 | Closed |
|
|
LCM
57
Laurion Capital Management
New York
| – | -$481K | -178 | Closed |
|
|
TCIM
58
TIAA CREF Investment Management
New York
| – | -$448K | -165 | Closed |
|
|
GPCM
59
Granite Point Capital Management
Boston,
Massachusetts
| – | -$304K | -113 | Closed |
|
|
SO
60
STRS Ohio
Columbus,
Ohio
| – | -$67K | -25 | Closed |
|
|
CCA
61
Catalyst Capital Advisors
Huntington,
New York
| – | -$9K | -3 | Closed |
|
62
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$777 | +1 | New |
|
VYNE Hedge Fund Activity: Q2 2018 in Review
48 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2018, worth a combined $116M — down 80% from $579M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VYNE and 13 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 14 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $3.37M. The largest seller was Deerfield Management, exiting entirely with an estimated $16M sold.
- 48 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2018, down from 49 in Q1 2018.
- Funds reported $116M of VYNE Therapeutics stock for Q2 2018, down 80% quarter-over-quarter.
- 13 funds opened new VYNE Therapeutics positions in Q2 2018 and 14 closed out, a net change of -1 holder.
- The largest VYNE Therapeutics buyer in Q2 2018 was DAFNA Capital Management, an estimated $3.37M added.
- The largest VYNE Therapeutics seller in Q2 2018 was Deerfield Management, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2018.